Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL593 first-in-human phase 1/2 study in healthy participants and participants with FTD-GRN
NL-OMON53476Phase 2Not yet recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jan 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DNL593 in frontotemporal dementia (FTD) (3 arms), sponsored by Denali Therapeutics Inc. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
DNL593
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON53476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53476.